Lifetime direct healthcare costs of treating colorectal cancer: a systematic review

Nazim Bhimani (), Geoffrey YM Wong, Charles Molloy, Mbathio Dieng, Patrick J Kelly and Thomas J Hugh
Additional contact information
Nazim Bhimani: Acute Services Building, Royal North Shore Hospital
Geoffrey YM Wong: Acute Services Building, Royal North Shore Hospital
Charles Molloy: Acute Services Building, Royal North Shore Hospital
Mbathio Dieng: University of Sydney
Patrick J Kelly: University of Sydney
Thomas J Hugh: Acute Services Building, Royal North Shore Hospital

The European Journal of Health Economics, 2023, vol. 24, issue 4, No 4, 513-537

Abstract: Abstract Colorectal cancer is a global public health issue and imposes a significant economic burden on populations and healthcare systems. This paper systematically reviews the literature to estimate the direct costs of colorectal cancer incurred during different phases of treatment (initial, continuing and end of life). MEDLINE, EMBASE, Web of science, Evidence-based medicine reviews: National health service economic evaluation database guide, econlit and grey literature from the 1st of January 2000 to the 1st of February 2020. The methodological quality of the included studies was assessed using the Evers’ Consensus on health economic criteria checklist. In total, 39,489 records were retrieved, and 17 studies were included. Costs by phase of treatment varied due to heterogeneity. However, studies that examined average costs for each phase of treatment showed a V-shaped distribution where the initial and end of life phases contribute the most and the continuing phase the least. The initial phase ranged from $7,893 to $60,289; the continuing annual phase ranged from $2,323 to $15,744; and the end of life phase ranged from $15,916 to $99,687. Studies that provided the total cost of each phase conversely showed that the continuing phase was the highest contributor to the cost of treating CRC. This study estimates the cost of the contemporary management of colorectal cancer despite the methodological heterogeneity. These costs place a heavy burden on healthcare providers, patients and their families. Identifying these costs can impact health care budgets and guide policymakers in making informed decisions for the future.

Keywords: Costs and cost analysis; Cost of illness; Colorectal cancer; Systematic review; Treatment; Phase of care (search for similar items in EconPapers)
JEL-codes: H5 I1 I18 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01497-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:4:d:10.1007_s10198-022-01497-z

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-022-01497-z

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().